Skip to main content

Catalyst Calendar

Scope

Thu, Sep 10, 2026

1 updates
ERAS
8:00 AM

Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium

Oral presentation to share updated monotherapy clinical data for ERAS-0015 including additional patients and longer follow-up, expanding on the previously reported preliminary results from the ongoing AURORAS-1 Phase 1 trial Poster presentation to share nonclinical combination data of ERAS-0015 and

Presentation / Abstract • Phase 1ENA oral presentation Fri, Nov 20, 2026, 12:30 PM Central European Timeerasca.com

Tue, Sep 8, 2026

1 updates

Mon, Aug 24, 2026

1 updates

Tue, Aug 11, 2026

1 updates
ERAS
4:01 PM

Erasca Reports Second Quarter 2026 Business Updates and Financial Results

Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination ERAS-0015 program advancing toward three potentially registration-enabling trials in pancreatic

Interim Data • Phase 1Interim data Wed, Dec 31, 2025erasca.com

Mon, Aug 10, 2026

2 updates
ERAS
4:01 PM

Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that, in connection with the

erasca.com

Wed, Jul 15, 2026

1 updates

Mon, Jul 13, 2026

3 updates
ERAS
11:10 PM

Erasca Announces Pricing of Upsized Public Offering of Common Stock

SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an upsized public

erasca.com
ERAS
4:19 PM

Erasca Announces Proposed Public Offering of $500 Million of Common Stock

SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it intends to offer and sell,

erasca.com
ERAS
4:01 PM

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated at RDEs Promising combination potential, including no DLTs, encouraging safety data, and

Interim Data • Phase 1oral presentation Mon, May 25, 2026erasca.com